Your shopping cart is currently empty

Benzo[a]pyrene (3,4-Benzopyrene) exhibits lung carcinogenicity in animal models and is commonly used for lung cancer modeling and chemoprevention research.
![Benzo[a]pyrene](https://cdn.targetmol.com/group3/M00/02/65/CgoaEWY7LKeEcJWwAAAAAGm2G90541.png)
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $35 | In Stock | In Stock | |
| 25 mg | $73 | In Stock | In Stock | |
| 50 mg | $123 | In Stock | In Stock | |
| 100 mg | $197 | In Stock | In Stock | |
| 200 mg | $293 | - | In Stock | |
| 500 mg | $496 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $40 | In Stock | In Stock |
| Description | Benzo[a]pyrene (3,4-Benzopyrene) exhibits lung carcinogenicity in animal models and is commonly used for lung cancer modeling and chemoprevention research. |
| In vivo | lung tumorigenesis induced by Benzo[a]pyrene(B[a]P) was dose dependent in female A/J mice.?The incidence of hyperplasia values in females treated with 0.25, 0.50, and 1.0 mg B[a]P were significantly higher than in the vehicle-treated group.?The incidence of adenoma in females receiving 1.0 mg B[a]P was significantly higher than in the vehicle group.?The multiplicity of hyperplasia in females receiving 0.50 or 1.0 mg B[a]P was significantly higher than in the vehicle group.?The multiplicity of adenoma in the group treated with 1.0 mg was also significantly higher than in the vehicle group.?The incidences of hyperplasia and adenoma in female A/J mice were significantly increased by B[a]P in a dose-dependent manner.?Proliferative lesions in the lungs were classified as bronchiolar-alveolar hyperplasia or adenoma, and no malignant neoplasms (adenocarcinoma) were observed[1]. |
| Animal Research | After a 1- or 2-week acclimatization period, 360 adult male A/J mice and 520 adult female A/J mice were used for the experiment.?Mice were allocated, using a body weight-based randomization process, to a total of 22 groups.?Briefly, each animal received a single intraperitoneal administration of one of the initiators, at one of the indicated doses, on day 1.?The animals were observed daily for clinical signs and mortality, and body weights were measured weekly.?Following an overnight fast at 26 weeks after dosing, all mice were anesthetized with sevoflurane and weighed.?They were then sacrificed by exsanguination from the abdominal aorta and caudal vena cava and subjected to necropsy[1]. |
| Synonyms | 3,4-Benzopyrene |
| Molecular Weight | 252.31 |
| Formula | C20H12 |
| Cas No. | 50-32-8 |
| Smiles | C12=C3C4=CC=C1C=5C(C=C2C=CC3=CC=C4)=CC=CC5 |
| Relative Density. | 1.1549 g/cm3 (Estimated) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 9.09 mg/mL (36.03 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.96 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.